COVID-19 and pregnancy : A European study on pre- and post-infection medication use
© 2024. The Author(s)..
PURPOSE: The COVID-19 pandemic has impacted medication needs and prescribing practices, including those affecting pregnant women. Our goal was to investigate patterns of medication use among pregnant women with COVID-19, focusing on variations by trimester of infection and location.
METHODS: We conducted an observational study using six electronic healthcare databases from six European regions (Aragon/Spain; France; Norway; Tuscany, Italy; Valencia/Spain; and Wales/UK). The prevalence of primary care prescribing or dispensing was compared in the 30-day periods before and after a positive COVID-19 test or diagnosis.
RESULTS: The study included 294,126 pregnant women, of whom 8943 (3.0%) tested positive for, or were diagnosed with, COVID-19 during their pregnancy. A significantly higher use of antithrombotic medications was observed particularly after COVID-19 infection in the second and third trimesters. The highest increase was observed in the Valencia region where use of antithrombotic medications in the third trimester increased from 3.8% before COVID-19 to 61.9% after the infection. Increases in other countries were lower; for example, in Norway, the prevalence of antithrombotic medication use changed from around 1-2% before to around 6% after COVID-19 in the third trimester. Smaller and less consistent increases were observed in the use of other drug classes, such as antimicrobials and systemic corticosteroids.
CONCLUSION: Our findings highlight the substantial impact of COVID-19 on primary care medication use among pregnant women, with a marked increase in the use of antithrombotic medications post-COVID-19. These results underscore the need for further research to understand the broader implications of these patterns on maternal and neonatal/fetal health outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:80 |
|---|---|
| Enthalten in: |
European journal of clinical pharmacology - 80(2024), 5 vom: 10. Apr., Seite 707-716 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hurley, Eimir [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-bacterial agents |
|---|
| Anmerkungen: |
Date Completed 09.04.2024 Date Revised 11.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00228-024-03639-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368373630 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368373630 | ||
| 003 | DE-627 | ||
| 005 | 20240411232327.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240213s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00228-024-03639-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1372.xml |
| 035 | |a (DE-627)NLM368373630 | ||
| 035 | |a (NLM)38347228 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hurley, Eimir |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 and pregnancy |b A European study on pre- and post-infection medication use |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.04.2024 | ||
| 500 | |a Date Revised 11.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a PURPOSE: The COVID-19 pandemic has impacted medication needs and prescribing practices, including those affecting pregnant women. Our goal was to investigate patterns of medication use among pregnant women with COVID-19, focusing on variations by trimester of infection and location | ||
| 520 | |a METHODS: We conducted an observational study using six electronic healthcare databases from six European regions (Aragon/Spain; France; Norway; Tuscany, Italy; Valencia/Spain; and Wales/UK). The prevalence of primary care prescribing or dispensing was compared in the 30-day periods before and after a positive COVID-19 test or diagnosis | ||
| 520 | |a RESULTS: The study included 294,126 pregnant women, of whom 8943 (3.0%) tested positive for, or were diagnosed with, COVID-19 during their pregnancy. A significantly higher use of antithrombotic medications was observed particularly after COVID-19 infection in the second and third trimesters. The highest increase was observed in the Valencia region where use of antithrombotic medications in the third trimester increased from 3.8% before COVID-19 to 61.9% after the infection. Increases in other countries were lower; for example, in Norway, the prevalence of antithrombotic medication use changed from around 1-2% before to around 6% after COVID-19 in the third trimester. Smaller and less consistent increases were observed in the use of other drug classes, such as antimicrobials and systemic corticosteroids | ||
| 520 | |a CONCLUSION: Our findings highlight the substantial impact of COVID-19 on primary care medication use among pregnant women, with a marked increase in the use of antithrombotic medications post-COVID-19. These results underscore the need for further research to understand the broader implications of these patterns on maternal and neonatal/fetal health outcomes | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-bacterial agents | |
| 650 | 4 | |a Antithrombotic medications | |
| 650 | 4 | |a Antiviral agents | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Drug utilization study | |
| 650 | 4 | |a Pregnancy | |
| 650 | 4 | |a Steroids | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 700 | 1 | |a Geisler, Benjamin P |e verfasserin |4 aut | |
| 700 | 1 | |a Lupattelli, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Poblador-Plou, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Lassalle, Régis |e verfasserin |4 aut | |
| 700 | 1 | |a Jové, Jérémy |e verfasserin |4 aut | |
| 700 | 1 | |a Bernard, Marie-Agnes |e verfasserin |4 aut | |
| 700 | 1 | |a Sakr, Dunia |e verfasserin |4 aut | |
| 700 | 1 | |a Sanfélix-Gimeno, Gabriel |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-Saez, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Bernal, Clara L |e verfasserin |4 aut | |
| 700 | 1 | |a Sabaté, Mònica |e verfasserin |4 aut | |
| 700 | 1 | |a Ballarín, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Aguilera, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Jordan, Sue |e verfasserin |4 aut | |
| 700 | 1 | |a Thayer, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Farr, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Saira |e verfasserin |4 aut | |
| 700 | 1 | |a Bartolini, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Limoncella, Giorgio |e verfasserin |4 aut | |
| 700 | 1 | |a Paoletti, Olga |e verfasserin |4 aut | |
| 700 | 1 | |a Gini, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Maglanoc, Luigi A |e verfasserin |4 aut | |
| 700 | 1 | |a Dudukina, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Ehrenstein, Vera |e verfasserin |4 aut | |
| 700 | 1 | |a Alsina, Ema |e verfasserin |4 aut | |
| 700 | 1 | |a Vaz, Tiago A |e verfasserin |4 aut | |
| 700 | 1 | |a Riera-Arnau, Judit |e verfasserin |4 aut | |
| 700 | 1 | |a Sturkenboom, Miriam C J M |e verfasserin |4 aut | |
| 700 | 1 | |a Nordeng, Hedvig M E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of clinical pharmacology |d 1971 |g 80(2024), 5 vom: 10. Apr., Seite 707-716 |w (DE-627)NLM000099538 |x 1432-1041 |7 nnns |
| 773 | 1 | 8 | |g volume:80 |g year:2024 |g number:5 |g day:10 |g month:04 |g pages:707-716 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00228-024-03639-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 80 |j 2024 |e 5 |b 10 |c 04 |h 707-716 | ||